This announcement is a separate document:
科研製薬：原発性腋窩多汗症治療剤「エクロック」の韓国における販売承認申請の提出について
Kaken Pharmaceutical: Submission of a sales approval application for the treatment of primary axillary hyperhidrosis “ECLOC” in South Korea
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.